ClinicalTrials.gg
CompletedNCT03261999Updated May 4, 2020Results posted

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

A Phase 3 interventional study of Leuprolide Mesylate in Prostatic Neoplasms, sponsored by Foresee Pharmaceuticals Co., Ltd.. Completed at 21 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-04.

Sponsored by Foresee Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
690th of 3,023
144 · median 48
Started
2017
with 148 others
Phase 3
284 of 3,596
42 open now
Registered
2,087th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 690th largest by enrollment of the 3,023 interventional ones that give a count, is one of 149 that started in 2017, is one of 284 in phase 3, and was the 2,087th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.

Read the detailed description

This is a multi-national, multi-center, open-label, single-arm study. All subjects will be males with prostate cancer judged to be candidates for medical androgen ablation therapy and all will receive two injections of LMIS 25 mg twelve-week apart in an unblinded fashion.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostate Neoplasm Cancer Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged ≥ 18 years old
  2. Males with confirmed carcinoma of the prostate
  3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
  4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
  5. (ECOG) Performance score ≤ 2
  6. of at least 18 months
  7. Laboratory values

    • ≥ 1,500 cells/µL
    • ≥ 100,000 cells/µL
    • ≥ 10 gm/dL
    • Total ≤ 1.5 × (ULN)
    • (SGOT) ≤ 2.5 × ULN
    • ALT (SGPT) ≤ 2.5 × ULN
    • Serum creatinine ≤ 1.5 mg/dL
    • Lipid profile within acceptable range according to investigator's opinion
    • Serum glucose within acceptable range according to investigator's opinion
    • HgbA1c within acceptable range according to investigator's opinion
    • Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
    • Serum glucose within acceptable range according to investigator's judgement
    • Urinalysis within normal range according to the investigator's judgment
  8. Agree to use male methods during study trial
  9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  10. All aspects of the protocol explained and written obtained

Exclusion criteria

Exclusion Criteria:

  1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
  2. Receipt of any vaccination (including influenza) within 4 weeks of screening visit
  3. History of blood donation within 2 months of screening visit
  4. History of anaphylaxis to any LH-RH analogues
  5. Receipt of any LHRH suppressive therapy within 6 months of screening visit
  6. Major surgery, including any prostatic surgery, within 4 weeks of screening visit
  7. History and concomitant clinical and radiographic evidence of central nervous system/spinal cord and subjects at risk for spinal cord compression
  8. Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
  9. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
  10. History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
  11. abnormal and/or history of clinically significant cardiovascular disease as judged by the investigator
  12. History of drug and/or alcohol abuse within 6 months of Baseline
  13. to leuprolide or an LHRH agonist as indicated on package labeling
  14. Use of 5-alpha reductase inhibitor within the last 6 months of screening visit
  15. History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac > 9.5% or urine glycosuria > 1.0 g/dL should be excluded.
  16. Use of systemic at a dose >10 mg/d or anti-androgens
  17. Use of any agent within 4 weeks of screening visit
  18. Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except for those listed in the permitted Concomitant Treatment section.
  19. Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Leuprolide Mesylate 25mg

    All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate. The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168.

    Drug: Leuprolide Mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Leuprolide Mesylate (LMIS 25mg)

    The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) from Day 28 through Day 168.

    Time frame: 168 days

Secondary outcomes

  1. Number of Participants With Adverse Events

    Determining the safety and tolerability of LMIS 25 mg based on adverse events (AEs).

    Time frame: 168 days

07

Results

Posted May 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneLeuprolide Mesylate 25mg
Started144
Itt144
Pp132
Completed129
Not completed15

Outcome measures

PrimaryEfficacy of Leuprolide Mesylate (LMIS 25mg)

The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) from Day 28 through Day 168.

Time frame:
168 days
Reported as:
Number · Percentage of participants
Efficacy of Leuprolide Mesylate (LMIS 25mg)
Percentage of participantsLeuprolide Mesylate 25mg
Efficacy of Leuprolide Mesylate (LMIS 25mg)97.9 (93.5 to 99.3)
SecondaryNumber of Participants With Adverse Events

Determining the safety and tolerability of LMIS 25 mg based on adverse events (AEs).

Time frame:
168 days
Reported as:
Number · subjects
Number of Participants With Adverse Events
subjectsLeuprolide Mesylate 25mg
TEAE90
Drug-related TEAE53
SAE9

Adverse events

Collected over 168 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Mesylate 25mg0/144 (0%)9/144 (6.3%)70/144 (48.6%)
Most frequent serious events
Most frequent serious events
EventLeuprolide Mesylate 25mg
Acute myocardial infarctionCardiac disorders1/144
Pancreatitis acuteGastrointestinal disorders1/144
Drug-induced liver injuryHepatobiliary disorders1/144
Tendon ruptureInjury, poisoning and procedural complications1/144
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/144
Oropharyngeal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/144
Cerebrovascular accidentNervous system disorders1/144
SciaticaNervous system disorders1/144
Urethral stenosisRenal and urinary disorders1/144
Rehabilitation therapySurgical and medical procedures1/144
Most frequent other events
Most frequent other events
EventLeuprolide Mesylate 25mg
hot flushVascular disorders35/144
HypertensionVascular disorders16/144
weight increasedInvestigations11/144
Injection site haemorrhageGeneral disorders8/144

Baseline characteristics

Age, Continuous
Age, Continuous(years)Leuprolide Mesylate 25mg
Mean69.8 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Mesylate 25mg
Female0
Male144
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leuprolide Mesylate 25mg
Hispanic or Latino4
Not Hispanic or Latino4
Unknown or Not Reported136
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leuprolide Mesylate 25mg
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American1
White127
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Leuprolide Mesylate 25mg
South Korea16
United States8
Czechia9
Slovakia34
Lithuania77
Diagnosis (days) of prostate carcinoma history
Diagnosis (days) of prostate carcinoma history(days)Leuprolide Mesylate 25mg
Mean842.7 ± 1348.9
08

Study locations

21 sites
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
  • Arizona Institute of Urology
    Tucson, Arizona 85704, United States
  • The Urology Center of Colorado
    Denver, Colorado 80211, United States
  • Carolina Clinical Trials, LLC
    Concord, North Carolina 28025, United States
  • Urology San Antonio, P.A
    San Antonio, Texas 78229, United States
  • Urology of Virginia, PLLC
    Virginia Beach, Virginia 23462, United States
  • Fakultní nemocnice Hradec Králové, Urologická klinika
    Hradec Králové, 500 05, Czechia
  • Uromedical Center Olomouc
    Olomouc, 779 00, Czechia
  • Thomayerova nemocnice, Urologické oddělení
    Praha, 140 59, Czechia
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, 41931, Korea, Republic of
  • National Cancer Center
    Gyeonggi-do, 10408, Korea, Republic of
  • Seoul National University Bundang Hosptal
    Gyeonggi-do, 13620, Korea, Republic of
  • Hallym University Sacred Heart Hospital
    Gyeonggi-do, 14068, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, 50009, Lithuania
  • Klaipėda University Hospital
    Klaipėda, 92288, Lithuania
  • National Cancer Institute
    Vilnius, 08660, Lithuania
  • Vilnius University Hospital, Santaros klinikos
    Vilnius, 08661, Lithuania
  • UROCENTRUM MILAB, s.r.o.
    Prešov, 080 01, Slovakia
  • Fakultná nemocnica s poliklinikou Žilina Urológia
    Žilina, 012 07, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2018, 13 months.

Results were first posted in May 2020, 1 year 5 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 13 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2017
First posted
Aug 25, 2017
StartActual
Sep 26, 2017
Primary completionActual
Nov 19, 2018
CompletionActual
Feb 1, 2019
Results first posted
May 4, 2020
Last update
May 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03261999
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Aug 25, 2017
Start date
Sep 26, 2017
Primary completion
Nov 19, 2018
Completion
Feb 1, 2019
Results posted
May 4, 2020
Last update
May 4, 2020

Study contacts

John Mao, PhD
study director · Foresee Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide mesylate

Start the discussion